Cutibacterium acnes bacteriophage therapy: exploring a new frontier in acne vulgaris treatment
- 7 December 2024
- journal article
- review article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-12
Abstract
The skin microbiome, encompassing a variety of microorganisms, plays a critical role in skin health and function. Acne vulgaris, affecting approximately 9.4% of the global population, is a prevalent skin condition primarily targeting pilosebaceous units rich in sebaceous glands. The condition is influenced by factors such as hormonal changes, sebaceous gland dysfunction, and the activity of Cutibacterium acnes, a gram-positive bacterium linked to acne development. The skin’s immune system, particularly keratinocytes with pattern recognition receptors like Toll-like receptors (TLRs), plays a crucial role in recognizing and responding to bacterial presence. The onset of acne is often linked to adolescence, marked by significant hormonal fluctuations. Genetics also plays a role, with family history being a notable risk factor. Acne is characterized by distinct alterations in the C. acnes composition, with specific phylotypes associated with either commensal or pathogenic behavior. Traditional treatments include antibiotics, but the rise of antibiotic resistance has led to exploring alternative therapies, such as bacteriophage therapy. Bacteriophages offer a targeted approach to treating acne by targeting C. acnes strains, potentially reducing antibiotic resistance and enhancing treatment efficacy. Phage therapy shows promise, but further research is needed to fully understand its effectiveness and potential in clinical applications. Additionally, combining phages with antibiotics may offer a synergistic approach to overcoming antibiotic resistance and managing acne.Keywords
This publication has 45 references indexed in Scilit:
- Safety and efficacy of phage application in bacterial decolonisation: a systematic reviewThe Lancet Microbe, 2024
- The Microbiome and Acne: Perspectives for TreatmentDermatology and Therapy, 2024
- Characterization of the newly isolated phage Y3Z against multi-drug resistant Cutibacterium acnesMicrobial Pathogenesis, 2023
- Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the futureFolia Microbiologica, 2023
- Bacteriophage therapy for human musculoskeletal and skin/soft tissue infectionsClinical Microbiology and Infection, 2023
- Phage therapy: From biological mechanisms to future directionsCell, 2023
- Cutibacterium acnes evolution: One pore at a timeCell Host & Microbe, 2022
- Phage therapy of wound-associated infectionsFolia Microbiologica, 2022
- Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future PerspectivesDermatology and Therapy, 2018
- Natural solution to antibiotic resistance: bacteriophages ‘The Living Drugs’World Journal of Microbiology and Biotechnology, 2014